ACHV
Achieve Life Sciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$7.98
+0.88%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$7.90
From 52W high−6.45%
Volume2.83M
Market cap$821.16M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$7.90
From 52W high
−6.45%
Volume
2.83M
Market cap
$821.16M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.8x
P/E (TTM)
—
RSI (14)
56.3
MomentumView details →
1D Return
+0.88%
YTD Return
+59.36%
SummaryUpdated Jun 1, 2026
Achieve Life Sciences, Inc. (NASDAQ:ACHV) is a clinical-stage pharmaceutical company founded in 1995 and based in Vancouver, Canada. The company focuses on developing cytisinicline, a plant-based alkaloid derived from the golden rain tree, as a smoking cessation and nicotine addiction treatment. After decades of development, Achieve is preparing to submit its New Drug Application (NDA) to the FDA in mid-2025, positioning itself to potentially launch the first new FDA-approved nicotine dependence treatment in nearly 20 years.
Similar companies
Latest newsMore news →
Achieve Life Sciences granted new hire inducement stock options for 315,000 shares and RSUs for 283,000 shares to seven new employees under its 2024 Equity Inducement Plan.17d agoAchieve Life Sciences announced that its board approved granting stock options for 1,190,000 shares and RSUs for 125,000 shares of common stock to six new employees under its 2024 Equity Inducement Plan.51d agoAchieve Life Sciences appointed Jeff Farrow and Reid Waldman, M.D. as directors, effective May 29, 2026, each receiving stock options to purchase 47,250 shares vesting monthly over three years.111d ago